National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 54015 [2024-14202]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 125 / Friday, June 28, 2024 / Notices
Dated: June 25, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
[FR Doc. 2024–14252 Filed 6–27–24; 8:45 am]
BILLING CODE 4140–01–P
Fiscal Year (FY) 2024 Notice of
Supplemental Funding Opportunity
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Multidisciplinary Research
to Accelerate Hepatitis B Cure in Persons
Living with HIV and HBV (U19 Clinical Trial
Not Allowed).
Date: July 25–26, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Kristina S. Wickham,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892, 301–761–5390,
kristina.wickham@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: June 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–14202 Filed 6–27–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:25 Jun 27, 2024
Jkt 262001
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) is supporting one
supplement (in scope of the parent
award) for the Cooperative Agreement
for National Suicide Prevention Lifeline
and Disaster Distress Helpline recipient,
Mental Health Association of New York
City, Inc. (DBA Vibrant Emotional
Health), funded in FY 2021 under
Notice of Funding Opportunity (NOFO)
SM 21–005. The recipient may receive
up to $80,000,000 and has a project end
date of September 29, 2026. The
supplemental funding will be used to
maintain 988 operations and services,
both at local levels and across all
backup, chat, text, LGBTQI+ youth,
Spanish language, and videophone
based services. This funding will ensure
continuation of all 988 services and
supports.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Mary Woodruff, Public Health Advisor,
988 and Behavioral Health Crisis
Coordinating Office, Substance Abuse
and Mental Health Services
Administration, 5600 Fishers Lane,
Rockville, MD 20857, telephone 240–
276–1733; email: mary.woodruff@
samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title:
Cooperative Agreement for the National
Suicide Prevention Lifeline and Disaster
Distress Helpline, SM–21–005.
Assistance Listing Number: 93.243.
Authority: Section 520E–3 (42 U.S.C.
290bb–36c) of the Public Health Service
Act, as amended.
Justification: The 988 Suicide and
Crisis Lifeline Cooperative Agreement
(988 Lifeline) manages, enhances, and
strengthens the 988 Lifeline network
that routes individuals in the United
States to a network of certified crisis
centers that links to local emergency,
mental health, and social services
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
54015
resources. The 988 Lifeline is a 24/7
confidential suicide and crisis hotline
providing phone, chat, and text services
for anyone in the United States
experiencing a suicidal crisis or in
emotional distress. This supplemental
funding will ensure continuation of all
active services, including continuing
expanded access for high-risk
populations, improving access to
services to ensure equity of access, and
supporting infrastructure to ensure
stability, safety, privacy, and connection
of service.
Since 2005, Vibrant Emotional Health
has provided oversight and management
of the Suicide Prevention Lifeline and
its local call centers, backup centers,
Spanish network, and chat/text
functions with a network of over 215+
centers in all fifty states. Vibrant
Emotional Health has the infrastructure,
experience, and national reach to work
with the backup centers, language
services, and chat/text organizations to
address the increased contact volumes
expected in 2023 and beyond. With the
transition to 988 accomplished,
consistent services, such as ensuring
access to the local and national Lifeline
backup centers, geo-routing, language
services, system evaluation and data
reporting, and access to specialized care
for populations to be known at higher
risk for suicide, are required to fully
realize the potential impact to 988
contact service. Through this
supplemental funding, SAMHSA and
Vibrant can ensure capacity to address
increased call, chat and text volume
following 988 implementation, further
develop connection and support for
individuals at higher risk of suicide, and
strengthen the efficiency and customer
experience of the network through
unified technology.
This is not a formal request for
application. Assistance will only be
provided to the recipient, funded in FY
2021 under the Cooperative Agreement
for the National Suicide Prevention
Lifeline and Disaster Distress Helpline
(SM–21–005) based on the receipt of a
satisfactory application and associated
budget that is approved by a review
group.
Savannah Kidd,
Supervisory Public Health Analyst.
[FR Doc. 2024–14055 Filed 6–27–24; 8:45 am]
BILLING CODE 4162–20–P
E:\FR\FM\28JNN1.SGM
28JNN1
]]>Agencies
[Federal Register Volume 89, Number 125 (Friday, June 28, 2024)]
[Notices]
[Page 54015]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-14202]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Multidisciplinary Research to
Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (U19
Clinical Trial Not Allowed).
Date: July 25-26, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Kristina S. Wickham, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G22B,
Rockville, MD 20892, 301-761-5390, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: June 24, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-14202 Filed 6-27-24; 8:45 am]
BILLING CODE 4140-01-P
